Galectin Therapeutics | GALT - Selling And Administration Expenses

Stock Price
2.97
Daily Change
-0.01 -0.17%
Monthly
-4.97%
Yearly
103.08%
Q1 Forecast
2.88

Galectin Therapeutics reported $1.48M in Selling and Administration Expenses for its fiscal quarter ending in June of 2024.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Galectin Therapeutics USD 1.48M 110K Jun/2024
Gilead Sciences USD 1.78B 425M Dec/2025
Immunic USD -0.24 0.03 Sep/2024
Incyte USD 390.41M 61.33M Dec/2025
Merck USD 2.85B 215M Dec/2025